Daniel Tsai

Research Fellow | Pharmacoepidemiology, comparative effectiveness research, AsPEN, NeuroGEN

[Daniel Tsai @DanielHTTsai]

"A publicly accessible metadata of the 15 databases available to NeuroGEN researchers across North America, Europe, Asia, Oceania to facilitate the RWD use for assessment of disease burden and development of current and future treatments for neurological and mental disorders."

[Daniel Tsai @DanielHTTsai]

@Lai_Edw

[Daniel Tsai @DanielHTTsai]

Our study shows SGLT-2 inhibitors reduce the risk of all-cause mortality (HR: 0.77) and hepatic decompensation (HR: 0.89) in patients with type 2 diabetes and compensated cirrhosis. @BMCMedicine
https://t.co/f6XMnTIH5O

[Population Health Data Center, NCKU @PHData_center]

Talking about CCW during educational session this ACPE.
Always find something new when I approach this methodology every time.

[Population Health Data Center, NCKU @PHData_center]

Cyberport park is so romantic. The sunset is just breathtaking.

[ASN Publications @asnpublications]

New in #ASNKidney360: SGLT2 inhibitors were associated with lower nephrolithiasis risk compared to DPP4i and GLP-1RA in patients with diabetes. Read more: https://t.co/d1Hq1I6fcF

[Edward Lai @Lai_Edw]

Excited to share that our study has just been published in the #EuropeanHeartJournal! This is a nationwide case-crossover study to examine whether short-term increases in anticholinergic burden(#OHCA).

https://t.co/AeFhT4S0VC

[PEM Updates @PEMupd]

New Article: Epidemiology and Burden of Illness of Lennox-Gastaut Syndrome in Taiwan: A Retrospective Cohort Study https://t.co/AD1spuEQAz #PEM #FOAMed #PEMUPDATES

[Prof Ian Wong @Prof_IanWong]

"Emulating Six Cardiovascular Outcome Trials of Antidiabetic Drugs in Individuals with Type 2 Diabetes: Analyses Based on Real‐World Databases from Korea and Taiwan", has been published by our international team! Read https://t.co/rPoLEEMVtr

[Daniel Tsai @DanielHTTsai]

https://t.co/WCEIAexu59

[Daniel Tsai @DanielHTTsai]

No significant difference in IBD risk between SGLT2i vs DPP4i

Null results are just as essential, they refine expectations, guide better science, and prevent overhype.
https://t.co/GnxMiLFuzc

[Daniel Tsai @DanielHTTsai]

https://t.co/7QK0gDsCOD

[Daniel Tsai @DanielHTTsai]

Neonatal invasive candidiasis hits LMICs

#SGUL #CNPI #RWEquality

[Open Forum Infectious Diseases @OFIDJournal]

The burden of Neonatal Invasive Candidiasis in Low- and Middle-Income Countries: a systematic review and meta-analysis.

✅ Just Accepted
🔗 https://t.co/NfGNAyZRKf

[Daniel Tsai @DanielHTTsai]

@NCKU_official

[Daniel Tsai @DanielHTTsai]

Happy to get this piece published. A hard work emulating three trials to inform drug repurposing.
@Lai_Edw @albert_ch1210
#PHDCenter

[CMAJ @CMAJ]

SGLT2 inhibitors and chronic kidney disease:
SGLT2 inhibitors may be considered to reduce risk of chronic kidney disease mineral and bone disorders (CKD-MBD) in patients with type  2 diabetes mellitus and stage 1–3 CKD.
➡️ https://t.co/esmNjcwpTu

[Daniel Tsai @DanielHTTsai]

@Lai_Edw @albert_ch1210 @PHData_center

[Daniel Tsai @DanielHTTsai]

@TheBJPsych

[Daniel Tsai @DanielHTTsai]

We found that antipsychotic augmentation was associated with a reduced incidence of suicide attempt. However, after using the clone-censor-weight approach to control for time-lag bias, we no longer found any association of antipsychotic augmentation with reduced risks of suicide.

[Daniel Tsai @DanielHTTsai]

https://t.co/atv6Kw3eqi

[Daniel Tsai @DanielHTTsai]

@Lai_Edw @Avery_shue_he @albert_ch1210 @PHData_center @NCKU_official

[Mina T. @Mina__T]

We’re analyzing (early teaser) where the U.S. really gets its final drug dosages from—and early data is eye-opening.

This is why drug supply chains must be protected from strain—including #tariffs.

Global thinking is essential here.